Yahoo Web Search

Search results

1. • 

     Is Wegovy or Ozempic Better for Weight Loss?

     MediaFeed via AOL· 5 days ago

     Jacob Wackerhausen/Istockphoto The most common side effects of Ozempic include: Pancreatitis (inflammation of the pancreas) Diabetic retinopathy...

2. • 

     Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst - Glaukos...

     Benzinga· 6 days ago

     Thursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...

3. • 

     5 Fun Ways to Stay Fit With Your Partner—Without Going to the Gym

     Woman's Day· 5 hours ago

     Staying physically fit doesn’t require a gym membership, and it doesn’t have to be a solitary...

4. • 

     Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

     GuruFocus.com via Yahoo Finance· 1 day ago

     The company, a prominent biopharmaceutical entity focused on innovative therapies for eye diseases,...

5. • 

     Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements

     GuruFocus.com via Yahoo Finance· 11 hours ago

     The biopharmaceutical company, known for its focus on developing treatments for serious and rare...

6. • 

     EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal

     Market Watch· 2 days ago

     dropped nearly 30% in premarket trading Monday after the company said its experimental...

7. • 

     How to identify ultra-processed foods (UPFs) – and the surprising ones hiding in your cupboard

     The Telegraph via Yahoo News· 12 hours ago

     It’s now impossible to avoid warnings about the dangers of eating too much ultra-processed food...

8. • 

     Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript

     Insider Monkey via Yahoo Finance· 5 hours ago

     Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme...

9. • EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint

     Market Watch· 3 days ago

     EyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.

10. • 

      More adults have prediabetes however, very few know it

      KIII Corpus Christi· 2 hours ago

      According to the Centers for Disease Control, a health condition known as prediabetes affects 98...